免疫治疗联合放射治疗在转移性非小细胞肺癌中的临床研究进展

Advances in clinical studies of immunotherapy combined with radiotherapy in thetreatment of metastatic NSCLC

近年来,肺癌已经成为恶性肿瘤最重要的死因,其中非小细胞肺癌(NSCLC)隐匿起病、发展迅速、早期转移,易失去手术机会,预后差。在评估治疗转移性NSCLC过程中,研究者发现免疫治疗联合放射治疗能够更有效地控制NSCLC的转移。虽然免疫治疗肿瘤的方法一直是各国学者研究的热点,但目前临床上没有明显进展。近年来研发出来的一些新型药物能够特异性免疫识别和杀伤肿瘤细胞,已逐渐成为治疗肿瘤的新方法。与此同时,放射治疗可诱导产生多种免疫调节,潜在地影响免疫治疗的有效性。免疫治疗联合放射治疗已成为一种具有前瞻性的治疗方案。本研究就免疫治疗联合放射治疗在转移性NSCLC中的临床研究进展作一综述。

Recently,lung cancer has become the most important cause of death of solid tumors in the world.Non-small-cell lung cancer( NSCLC) is characterized by its occult onset,rapid development,early metastasis,loss of surgical opportunities,poor prognosis. In assessing the treatment of metastatic NSCLC,the researchers found that immunotherapy combined with radiation therapy can control the metastatic NSCLC more effectively. Although the method of immunotherapy of tumors has been a hot topic in the study of scholars,but there is no significant clinical progress. With the development of new drugs in these years,the ability to specifically identify and target tumor cells,has gradually become a new method of treatment of cancer. At the same time,radiotherapy can induce a variety of immune regulation,potentially affecting the effectiveness of immunotherapy. Immunotherapy combined with radiotherapy has become a promising treatment regimen. We reviewed the clinical progress of immunotherapy combined with radiotherapy in metastatic NSCLC.